MinorSodium-glucose cotransporter-2 (SGLT2) inhibitor×Tripeptide antioxidant (γ-glutamyl-cysteinyl-glycine); cofactor of glutathione S-transferase
Updated · Methodology
Mechanism
Dapagliflozin is metabolised mainly by UGT1A9 in the liver and kidneys, and CYP-mediated metabolism is a minor route. It neither inhibits nor induces CYP enzymes (Forxiga SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2). Glutathione is a tripeptide. It is not authorised as an oral medicine in Spain and is sold as a food supplement. Intestinal and hepatic gamma-glutamyltransferase breaks it down: in 7 healthy volunteers, 3 g of oral glutathione did not raise plasma glutathione (Witschi et al., 1992). With 250–1000 mg a day for 6 months, glutathione stores in blood rose by 17–35% (randomised trial, Richie et al., 2015). The combination with dapagliflozin has not been studied, and no interaction mechanism is known. Glutathione is not among the products that, according to the dapagliflozin SmPC, change its effect (Forxiga SmPC, EMA, section 4.5).
Symptoms
No symptoms caused by this combination have been described. Dapagliflozin can increase the diuretic effect of thiazide and loop diuretics and with them the risk of dehydration and hypotension. With insulin or sulfonylureas, it can increase the risk of hypoglycaemia (Forxiga SmPC, European Medicines Agency, EMA, section 4.5). Diabetic ketoacidosis is rare and may occur with blood glucose below 14 mmol/L. Its signs are nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness (Forxiga SmPC, EMA, section 4.4).
Management
The combination can be used and no dose change is needed. There are no data on an interaction, and no mechanism that would cause one is known (Forxiga SmPC, European Medicines Agency, EMA, section 4.5). If nausea, vomiting, abdominal pain, excessive thirst or unusual sleepiness appear, blood ketones are checked regardless of glucose levels, and dapagliflozin is stopped at once if ketoacidosis is confirmed (Forxiga SmPC, EMA, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Dapagliflozina (EU/1/12/795), sección 4.5 (2026)– EMA, Forxiga 10 mg comprimidos recubiertos con película (AstraZeneca AB, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 112795007, consultada 03.11.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.4, 4.5 y 5.2
- European journal of clinical pharmacology: The systemic availability of oral glutathione (1992)– Witschi A, et al. Eur J Clin Pharmacol. 1992;43(6):667-9. PMID 1362956
- European journal of nutrition: Randomized controlled trial of oral glutathione supplementation on body stores of glutathione (2015)– Richie JP Jr, et al. Eur J Nutr. 2015;54(2):251-63. PMID 24791752